Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MacroGenics, Inc.
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.
The Dutch firm’s dream to become the number one antibody drug conjugate technology provider by 2023 has been bolstered by a flurry of recent strategic collaborations, including one with MacroGenics.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Raven Biotechnologies